No Data
No Data
No Data
No Data
No Data
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discov
AccesswireMar 23 04:30
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
AccesswireMar 21 01:40
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
AccesswireMar 14 20:00
Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
AccesswireMar 11 19:00
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis
AccesswireFeb 23 20:30
Notice of Deficiency With Nasdaq Continued Listing Requirements
Yahoo FinanceJan 13 05:30
No Data
No Data